Researchers at the National Institutes of Health (NIH) in Bethesda, Maryland are investigating if durvalumab given in combination with tremelimumab can help patients diagnosed with Hepatocellular Carcinoma (HCC) or advanced biliary tract carcinoma (BTC) that has not responded to standard treatment. The results of this study may provide answers for a new treatment that may help patients with hepatocellular carcinoma or advanced biliary tract carcinoma for which standard treatment has not help.

**STUDY DESIGN:**
- Will receive a biopsy of the tumor.
- Will receive therapy divided into cycles, each lasting 28 days.
- Patients will receive only Durvalumab after their 4th therapy cycle.

For More Information

NIH Clinical Center
Office of Patient Recruitment
800-411-1222
TTY: 800-877-8339
Se habla español
Email: PRPL@cc.nih.gov
Online: [https://go.usa.gov/xpEKb](https://go.usa.gov/xpEKb)
NIH Study: 16-C-0135